Drug Trial Radar · NCT02456740
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
Last checked: Nov 20, 2026Latest source record: Oct 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
955
Actual
Start
Jul 17, 2015
Primary completion
Sep 5, 2016
Study completion Jun 19, 2017
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- May 28, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study was to evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days.
Conditions
- Migraine
Interventions
ErenumabDrug
Administered by subcutaneous injection once a month
PlaceboDrug
Administered by subcutaneous injection once a month
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Mean Monthly Migraine Days to the Last 3 Months of the Double-blind Treatment PeriodTime frame: 4-week baseline phase and the last 3 months (months 4, 5, and 6) of the 24-week double-blind treatment phase
Locations
129 sites in 13 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona
Research Site
Anaheim, California
Research Site
Encino, California
Research Site
Irvine, California
Research Site
Los Alamitos, California
Research Site
Newport Beach, California
Research Site
Rancho Mirage, California
Research Site
Redlands, California
Research Site
Sherman Oaks, California
Research Site
Simi Valley, California
Research Site
Spring Valley, California
Research Site
Boulder, Colorado
Research Site
East Hartford, Connecticut
Research Site
Stamford, Connecticut
Research Site
Waterbury, Connecticut
Research Site
Bradenton, Florida
Research Site
Jacksonville, Florida
Research Site
Leesburg, Florida
Research Site
Miami, Florida
Research Site
Ocala, Florida
Research Site
Orlando, Florida
Research Site
Sunrise, Florida
Research Site
West Palm Beach, Florida
Research Site
Atlanta, Georgia
Research Site
Boise, Idaho
Research Site
Evansville, Indiana
Research Site
Des Moines, Iowa
Research Site
Newton, Kansas
Research Site
Wichita, Kansas
Research Site
Edgewood, Kentucky
Research Site
Metairie, Louisiana
Research Site
New Orleans, Louisiana
Research Site
New Bedford, Massachusetts
Research Site
Worcester, Massachusetts
Research Site
Plymouth, Minnesota
Research Site
Kansas City, Missouri
Research Site
Springfield, Missouri
Research Site
St Louis, Missouri
Research Site
Amherst, New York
Research Site
Plainview, New York
Showing 40 of 129 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.